ConductScience.org, home

Comparison · NCT01187446-223f63d2

TSEBT Only vs TSEBT Plus Vorinostat: Complete Clinical Response (CCR)

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. TSEBT Only vs TSEBT Plus Vorinostat: Complete Clinical Response (CCR). Trial comparisons, record NCT01187446-223f63d2. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01187446-223f63d2

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2140.07570.476wilson
Risk in group 20.2310.08180.503wilson
Risk difference, group 1 minus group 2-0.0165-0.3220.285newcombe hybrid score
Risk ratio, group 1 over group 20.9290.2263.81log
Odds ratio, group 1 over group 20.9090.1485.58log
Number needed to treat, for one fewer participant with the outcome on TSEBT Only than on TSEBT Plus Vorinostat60.7from the risk difference intervalthe interval includes no difference

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1TSEBT Only• TSEBT as 12 grey (Gy), fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks.314OG000
Group 2TSEBT Plus Vorinostat
* TSEBT as 12 grey (Gy), fractionated at 2 Gy/cycle (each cycle requiring 2 days of treatment); 4 days each week; for a total of 3 weeks.~* Vorinostat 400 mg/day concurrent and continuing for 8 weeks total.
313OG001

Outcome

Type
PRIMARY
Title
Complete Clinical Response (CCR)
Description
Complete Clinical Response (CCR) at week 8 as determined by an Modified Severity-Weighted Assessment Tool (mSWAT) score of 0. mSWAT is an objective, quantitative, severity-weighted method to assess the extent of mycosis fungoides (MF) lesions, and is determined by total body surface area (%TBSA) of the lesion by a severity-weighting factor (1 = patch; 2 = plaque; 4 = tumor). O% TBSA produces a product of 0, indicating complete response.
Time frame
Week 8
Population

Source ClinicalTrials.gov

Trial

Title
Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides
NCT number
NCT01187446
Phases
PHASE1, PHASE2
Conditions
Cutaneous Lymphoma, Cutaneous T-cell Lymphoma
Interventions
Total skin electron beam therapy (TSEBT), Vorinostat
Lead sponsor
Stanford University
Results first posted
2017-11-20

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01187446-223f63d2